Methods for determining the risk of a systemic lupus erythematosus (SLE) patient to develop neuropsychiatric syndromes
US20180231565A1Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- IMMUNARRAY LTD
- Publication Date
- 2018-08-16
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
FIELD OF THE INVENTION
[0001] The present invention relates to methods for diagnosing neuropsychiatric syndromes concurrent with SLE. The present invention further relates to methods for determining whether an SLE patient is at risk of developing neuropsychiatric syndromes.BACKGROUND OF THE INVENTION
[0002] Systemic lupus erythematosus (SLE) is a chronic, recurrent, potentially fatal multisystem inflammatory disorder mainly affecting women. SLE is associated with a large spectrum of autoantibodies. IgG antibodies to more than 100 different antigens including DNA, nucleosomes, histones, viral antigens, transcription factors and more have been reported in different SLE patients (Sherer et al., 2004, Semin. Arthritis. Rheum. 34:501-37).
[0003] Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in SLE. Neuropsychiatric SLE (NPSLE) involves a wide range of nervous system disorders, and can affect 50% or more of SLE p...